A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections
Introduction. Iclaprim is a diaminopyrimidine antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI) due to Gram-positive pathogens.
Aim. This analysis evaluates patients with wound infections from two Phase 3 trials of ABSSSI.
Methodology. Six-hundred-two patients with wound infections from two Phase 3, double-blinded, randomized, multicenter, active controlled trials (REVIVE-1/–2) were evaluated in a post hoc analysis of iclaprim 80 mg compared with vancomycin 15 mg kg–1 administered intravenously every 12 h for 5–14 days. The primary endpoint was to determine whether iclaprim was non-inferior (10 % margin) to vancomycin in achieving a ≥20 % reduction from baseline in lesion size 48–72 h after starting study drug (early clinical response [ECR]). Safety was assessed.
Results. In REVIVE-1, ECR was 83.5 % with iclaprim versus 79.7 % with vancomycin (treatment difference 3.77%, 95 % CI −4.50%, 12.04%). In REVIVE-2, ECR was 82.7 % with iclaprim versus 76.3 % with vancomycin (treatment difference 6.38%, 95 % CI −3.35%, 16.12%). In the pooled dataset, iclaprim had similar ECR rates compared with vancomycin among wound infection patients (83.2 % vs 78.2 %) with a treatment difference of 5.01 % (95 % CI −1.29%, 11.32%). The safety profile was similar in iclaprim- and vancomycin-treated patients, except for a higher incidence of diarrhea with vancomycin (n=17) compared with iclaprim (n=6) and fatigue with iclaprim (n=17) compared with vancomycin (n=8).
Conclusion. Based on early clinical response, iclaprim achieved non-inferiority to vancomycin with a similar safety profile in patients with wound infections suspected or confirmed as caused by Gram-positive pathogens. Iclaprim may be a valuable treatment option for wound infections.
Pulido-CejudoA,
Guzmán-GutierrezM,
Jalife-MontañoA,
Ortiz-CovarrubiasA,
Martínez-OrdazJL et al. Management of acute bacterial skin and skin structure infections with a focus on patients at high risk of treatment failure. Ther Adv Infect Dis2017; 4:143–161 [View Article][PubMed]
RayGT,
SuayaJA,
BaxterR.
Microbiology of skin and soft tissue infections in the age of community-acquired methicillin-resistant Staphylococcus aureus
. Diagn Microbiol Infect Dis2013; 76:24–30 [View Article][PubMed]
SchneiderP,
HawserS,
IslamK.
Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg Med Chem Lett2003; 13:4217–4221 [View Article][PubMed]
OefnerC,
BanderaM,
HaldimannA,
LaueH,
SchulzH et al. Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity. J Antimicrob Chemother2009; 63:687–698 [View Article][PubMed]
HuangDB,
O'RiordanW,
OvercashJS,
HellerB,
AminF et al. A phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous Iclaprim vs vancomycin for the treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to gram-positive pathogens: REVIVE-1. Clin Infect Dis2018; 66:1222–1229 [View Article][PubMed]
HollandTL,
O'RiordanW,
McManusA,
ShinE,
BorgheiA et al. A phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to gram-positive pathogens (REVIVE-2 study). Antimicrob Agents Chemother2018; 62:e02580-17 [View Article][PubMed]
MoranGJ,
FangE,
CoreyGR,
DasAF,
De AndaC et al. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis2014; 14:2014705 [View Article][PubMed]
ArmstrongES,
ChitraS,
SirbuA,
Garrity-RyanL,
ManleyA et al. Efficacy of Omadacycline and Linezolid against characterized drug resistant S. aureus from combined Phase 3 ABSSSI studies. ASM Microbe2018
HuangDB,
CoreyGR,
HollandTL,
LodiseT,
O'RiordanW et al. Pooled analysis of the phase 3 revive trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections. Int J Antimicrob Agents2018; 52:233–240 [View Article][PubMed]
A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections